Portfolio company miRecule, the Antibody RNA Conjugate (ARC) therapeutics leader targeting rare neuromuscular diseases, announced an expansion of its strategic collaboration with Sanofi to accelerate the development of transformative treatments for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). The expanded agreement builds upon the companies’ successful partnership in advancing ARC therapies and will support the development of a best-in-class ARC candidate designed to suppress DUX4, the genetic driver of FSHD. “The expanded collaboration allows us to bring forward the optimal disease-modifying therapy for clinical advancement that meets the preclinical milestones established at the beginning of our partnership,” Dr. Anthony Saleh, CEO of Mirecule, commented, The approach to whch miRecule commits aims to address the root cause of the disease and deliver a potentially disease-modifying therapy for patients affected by the debilitating condition. Under the terms of the collaboration, Sanofi will continue to leverage its expertise in rare disease drug development and will remain responsible for downstream clinical development and global commercialization efforts. In reaffirming its strong commitment to the FSHD community, miRecule emphasizing its collaborative efforts with key stakeholders, including the FSHD Society, Friends of FSH Research, and the National Institute of Neurological Disorders and Stroke (NINDS) SBIR program. The company remains focused on advancing its groundbreaking ARC-based therapy toward clinical realization, with the goal of delivering meaningful impact for patients living with FSHD. Brown and White Ventures committed to investment in miRecule in December 2025.